Home Crystal structure of 10-oxysophoridine, C15H22N2O2
Article Open Access

Crystal structure of 10-oxysophoridine, C15H22N2O2

  • Ming Yan , Huan-Yong Li , Ding Luo , Si Chen , Yu-Bo Zhang , Yao-Lan Li EMAIL logo and Guo-Cai Wang ORCID logo EMAIL logo
Published/Copyright: November 2, 2020

Abstract

C15H22N2O2, orthorhombic, P212121a = 5.27590(10) Å, b = 10.3482(3) Å, c = 23.5372(6) Å, V = 1285.04(6) Å3, Z = 4, Rgt(F) = 0.0338, wRref(F2) = 0.0852, T = 100(1) K.

CCDC no.: 1974380

The molecular structure is shown in the Figure. Table 1 contains crystallographic data, and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colorless block
Size:0.12 × 0.11 × 0.10 mm
Wavelength:Cu Kα radiation (1.54184 Å)
μ:0.72 mm−1
Diffractometer, scan mode:SuperNova, Atlas S2, ω
θmax, completeness:73.3°, >99%
N(hkl)measured, N(hkl)unique, Rint:5493, 2410, 0.025
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2312
N(param)refined:172
Programs:CrysAlisPRO [1], Olex2 [2], SHELX [3], [4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
O10.1299 (3)0.03547 (13)0.25683 (6)0.0217 (3)
O20.5907 (3)0.54518 (14)0.50883 (6)0.0244 (4)
N10.3033 (3)0.13754 (15)0.33289 (7)0.0157 (4)
N20.5268 (3)0.47198 (15)0.41984 (7)0.0161 (4)
C20.3546 (4)0.01317 (18)0.36118 (8)0.0186 (4)
H2A0.315285−0.0573800.3355160.022*
H2B0.2477480.0047820.3945080.022*
C30.6319 (4)0.00597 (19)0.37860 (8)0.0195 (4)
H3A0.7388080.0087760.3450840.023*
H3B0.663963−0.0747430.3982820.023*
C40.6949 (4)0.11958 (19)0.41752 (8)0.0180 (4)
H4A0.8735670.1170310.4271860.022*
H4B0.5984870.1118790.4524480.022*
C50.6338 (4)0.24871 (18)0.38918 (8)0.0148 (4)
H50.7485970.2613490.3569210.018*
C60.3592 (4)0.25302 (18)0.36772 (8)0.0144 (4)
H60.2482320.2499850.4010830.017*
C70.3044 (4)0.38125 (18)0.33628 (8)0.0141 (4)
H70.1261860.4038570.3425870.017*
C80.3457 (4)0.36573 (19)0.27261 (8)0.0166 (4)
H8A0.3164830.4473950.2534690.020*
H8B0.5186780.3388670.2651770.020*
C90.1622 (4)0.26470 (18)0.25079 (8)0.0173 (4)
H9A−0.0099200.2950340.2564080.021*
H9B0.1883060.2529730.2103190.021*
C100.1951 (4)0.13650 (19)0.28051 (8)0.0162 (4)
C110.4691 (4)0.49179 (18)0.35926 (8)0.0154 (4)
H110.6299310.4903010.3384540.018*
C120.3466 (4)0.62430 (19)0.34931 (8)0.0193 (4)
H12A0.4774020.6901630.3483770.023*
H12B0.2612540.6244400.3128130.023*
C130.1571 (5)0.65614 (19)0.39581 (9)0.0228 (5)
H13A0.0293720.5889420.3981910.027*
H13B0.0732220.7373930.3875220.027*
C140.3006 (5)0.6659 (2)0.45170 (9)0.0264 (5)
H14A0.3918670.7472590.4523780.032*
H14B0.1787980.6674870.4825590.032*
C150.4862 (4)0.55779 (18)0.46229 (8)0.0184 (4)
C170.6777 (4)0.35723 (18)0.43260 (8)0.0180 (4)
H17A0.6342210.3260930.4702270.022*
H17B0.8559150.3803070.4327670.022*

Source of material

The dry roots of Sophora flavescens were purchased from Xi’an, Shanxi Province, China. Dried Powder (25.0 kg) was extracted three times with 95% ethanol at room temperature. The solution was concentrated in vacuum to get a residue (1.6 kg). The crude extract was suspended in water and adjusted pH to 4–5 with HCl, and then partitioned with chloroform. The aqueous layer was adjusted to pH 9–10 with ammonium hydroxide and extracted by chloroform. After evaporation of solvent, the chloroform soluble fraction (463 g) was obtained. This fraction was chromatographed on a silica gel column, eluted with CHCl3–CH3OH solvent system, which afforded six fractions (Fr. 1–7). The title compound was obtained from Fr.4 and crystallized in methanol.

Experimental details

Using Olex2 [2], the structure was solved with the ShelXT [3].

Comment

The plant S. flavescens belongs to Leguminosae family. It is widely distributed in western and central Asia, especially in northwest China [5]. Previous chemical investigations of S. flavescens have revealed that matrine-type alkaloids are the main chemical constituents of this plant [6], [7]. Traditionally, the seeds and roots of this plant have been used as traditional Chinese medicine for the treatment of rheumatism, fever, bacterial infection, and heart disease [8]. Because of their complex stereostructure and diverse biological effects, matrinetype alkaloids have become increasingly attractive targets for both pharmacologists and synthetic chemists.

The title compound was determined structurally as 10-oxysophoridine [9], which belongs to a class of quinolizidine alkaloids with unique 6/6/6/6 tetracyclic skeletons. It has the basic skeleton of two valerolactam and two piperidine groups. The C=O bond lengths 1.233(2)–1.234(2) Å, C-N and C-C bond lengths are within normal ranges [10].


Corresponding authors: Yao-Lan Li and Guo-Cai WangGuangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou510632, P. R. China, E-mail: ,

Award Identifier / Grant number: 2017YFC1703800

Award Identifier / Grant number: 81973190

Award Identifier / Grant number: 81803376

Funding source: Guangdong Basic and Applied Basic Research Foundation

Award Identifier / Grant number: 2020B1515020033

Funding source: Natural Science Foundation of Guangdong Province

Award Identifier / Grant number: 2018B030311020

Funding source: Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program

Award Identifier / Grant number: 2017BT01Y036

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Ming Yan and Huan-Yong Li contributed equally to this work.

  2. Research funding: This work was supported by grants from the National Key R&D Program of China (No. 2017YFC1703800), National Natural Science Foundation of China (Nos. 81973190, 81803376), Guangdong Basic and Applied Basic Research Foundation (No. 2020B1515020033), Natural Science Foundation of Guangdong Province (No. 2018B030311020), and Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01Y036).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Oxford Diffraction: CrysAlisPRO; Oxford Diffraction Ltd: Abingdon, Oxfordshire, England, 2006.Search in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

3. Sheldrick, G. M. Shelxt – integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Search in Google Scholar

4. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

5. Wu, Z. Y. Flora of China; Science Press: Beijing, 1994; p. 80.Search in Google Scholar

6. Atta-Ur-Rahman, A. U., Choudhary, M. I., Parvez, K., Ahmed, A., Akhtar, F., Nur-e-Alam, M., Hassan, N. M. Quinolizidine alkaloids from Sophora alopecuroides. J. Nat. Prod. 2000, 63, 190–192; https://doi.org/10.1021/np990351v.Search in Google Scholar

7. Yu, Y., Ding, P., Chen, D. Determination of quinolizidine alkaloids in Sophora medicinal plants by capillary electrophoresis. Anal. Chim. Acta 2004, 523, 15–20; https://doi.org/10.1016/j.aca.2004.06.070.Search in Google Scholar

8. Song, L. R., Hong, X., Ding, X. L., Zang, Z. Y. Dictionary of Modern Medicine; People’s Medical Publishing House: Beijing, 2001; pp. 1224–1226.Search in Google Scholar

9. Zhang, Y. B., Luo, D., Yang, L., Cheng, W., He, L. J., Kuang, G. K., Li, M. M., Li, Y. L., Wang, G. C. Matrine-type alkaloids from the roots of Sophora flavescens and their antiviral activities against the Hepatitis B virus. J. Nat. Prod. 2018, 81, 2259–2265; https://doi.org/10.1021/acs.jnatprod.8b00576.Search in Google Scholar

10. Jing-Min, Ye, Hui-Qing, He, Xu-Hong, J., Zhan-Mei, L., Xing-An, C., Zhao-Chang, He. The crystal structure of a matrine derivative, 13-(4-Cl-pyrrole)-matrine, C18H26ClN4O. Z. Kristallogr. NCS 2019, 234, 785–786.10.1515/ncrs-2019-0105Search in Google Scholar

Received: 2020-09-05
Accepted: 2020-10-12
Published Online: 2020-11-02
Published in Print: 2021-01-26

© 2020 Ming Yan et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of 3-oxo-urs-12-en-28-oic acid, C30H46O3·1/6H2O
  4. The crystal structure of (3S,12R,20R,24R)-3,12-diacetyl-20,24-epoxy-dammarane-3,12,25–triol–ethyl acetate (4/1), C34H56O6⋅ 0.25(C4H8O2)
  5. A new polymorph of tetrakis(dimethylammonium) catena-poly[tetrakis(μ2-sulfato-κ2O:O′)dizinc(II)], Zn2C8H32N4O16S4
  6. Crystal structure of 10-oxysophoridine, C15H22N2O2
  7. The crystal structure of (5R,8R,9R,10R,12R,13R,14R)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)tetradecahydro-3H-cyclopenta[a]phenanthrene-3,6(2H)-dione, C30H48O4
  8. Synthesis, crystal structure and optical property of 1,6-bis(p-tolylthio)pyrene, C30H22S2
  9. The crystal structure of hexakis(2-(pyridin-2-ylamino)pyridin-1-ium) decavanadate(V) dihydrate, C60H64N18O30V10
  10. Preparation and crystal structure of a cationic olefin polymerization precatalyst: (1,7-bis(2,6–dichlorophenyl)-1,7-di-aza-4-oxo-heptan-1,4,7-triyl)dimethyl zirconium(IV), C18H20Cl4N2OZr
  11. The crystal structure of fac-tricarbonyl(4,4-dimethyl-2,2-dipyridyl-κ2N,N′)- (pyrazole-κN)rhenium(I) nitrate, C18H16O3N4Re
  12. Synthesis and crystal structure of hexaaquacopper(II) 2,5-dicarboxyterephthalate, C10H16O14Cu
  13. The crystal structure of (8R,10R,12R,14R)- 12-hydroxy-16-(5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)- 4,4,8,10,14-pentamethyltetradecahydro-3H- cyclopenta[a]phenanthrene-3,6(2H)-dione, C30H48O5
  14. Structure of the mixed crystal (S)-(6-(bromo/chloro)-2-methoxy-2,6-dihydroquinolin-3-yl)(phenyl)methanol, C17H14Br0.5Cl0.5NO2
  15. The crystal structure of trans-tetraaqua-bis(4-acetylphenoxyacetato-κ1O)manganese(II), C20H26O12Mn
  16. Crystal structure of (E)-2-(4-fluoro-3-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
  17. Crystal structure of DL-α-(methylaminomethyl)benzyl alcohol, C9H13NO
  18. The crystal structure of dipentaerthritol hexanitrate, C10H16N6O19
  19. Crystal structure of N,N-diphenylformamide, C13H11NO
  20. Crystal structure of (E)-2-(3,5-bis(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen- 1(2H)-one, C20H14F6O2
  21. Crystal structure of ortho-methoxy benzaldehyde, C8H8O2 – a second polymorph and deposition of 3D coordinates
  22. Crystal structure of catena-poly[diaqua-bis(μ2-2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanoato-κ2O:O')-(2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanoato-κ2O,O')yttrium(III)], C51H79O11Y
  23. Crystal structure of benzylthiouronium chloride, C8H11ClN2S
  24. Synthesis and crystal structure of tert-butyl (2′R,3R,3′R,4aR,9aS)-1-acetyl-5-chloro-3″-methyl-2,5″,9′-trioxo-1″-phenyl-1″,4a′,5″,9a′-tetrahydro-1′H,3′H,9′H-dispiro[indoline-3,4′-xanthene-2′,4″-pyrazole]-3′-carboxylate, C36H32ClN3O7
  25. Crystal structure of 2-hydroxy-4-methoxy benzaldehyde, C8H8O3
  26. Crystal structure of poly[diaqua-(m3-3′,5′-dicarboxy-[1,1′-biphenyl]-3,4-dicarboxylato-K4O,O′:O″:O‴) cadmium(II)], C16H11O10Cd
  27. Crystal structure of {tetraaqua-bis(1-(4-hydroxy-2-oxotetrahydrofuran-3-yl)-2-((4aS,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethane-1-sulfonato-k2O,O') calcium(II)}-{triaqua-bis(1-(4-hydroxy-2-oxotetrahydrofuran-3-yl)-2-((4aS,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethane-1-sulfonato-k2O,O') calcium(II)} – water – acetone (1/1/8/2)
  28. Synthesis and crystal structure of bis{2-bromo-6-((E)-((4-((E)-1-(methoxy-imino)ethyl)phenyl)imino)methyl)phenolato- κ2N,O}zinc(II)-methanol(1/2), C65H60Br4N8O9Zn2
  29. Crystal structure of benzenesulphonic acid
  30. Crystal structure of N-benzyl-N-nicotinoyl-nicotine amide C19H15N3O2
  31. Crystal structure of poly[aqua(μ3-2,4-diamino-benzenesulfonato-κ4N:N′,O:O′)silver(I)], C12H18O8N4S2Ag2
  32. Crystal structure of 1,4-bis(methylpyridinium benzene) bis(1,2-dicyanoethene-1,2-dithiolato-κ2S:S)nickel(II), C26H18N6NiS4
  33. Crystal structure of the Cu(II) complex chlorido-(6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxylato-k2N,O)-(phenanthroline-k2N,N')copper(II), C23H15ClCuN4O3
  34. Crystal structure of phenarsazine chloride acetic acid solvate, C14H13AsClNO2
  35. Crystal structure of poly[aqua-(μ2-3,3′,4,5′-biphenyl tetracarboxylate- κ3O,O′:O′′) -(μ2-4,4′-bis(pyrid-4-yl)biphenyl-κ2N:N′)zinc(II)], C27H18NO9Zn
  36. Crystal structure of catena-poly[(μ2-3-amino-benzenedisulfonato-κ2N:O)-bis (3-methyl-isoquinoline-κN)silver(I)], C26H24N3O3SAg
  37. Crystal structure of 2-((4-Aminophenyl)thio)acetic acid, C8H9NO2S
  38. Crystal structure of phenarsazine chloride dimethylsulfoxide solvate, C14H15AsClNOS
  39. Synthesis and crystal structure of 2-azido-N-phenylacetamide, C8H8N4O
  40. Crystal structure of chlorido{hydridotris[3-phenyl-5-methylpyrazol-1-yl-κN3]borato}copper(II), C30H28BClCuN6
  41. Crystal structure of benzanthrone – a redetermination for correct molecular geometry and localization of hydrogen atoms
  42. Crystal structure of 4-bromobenzaldehyde – complete redetermination at 200 K, C7H5BrO
  43. Crystal structure and spectroscopic properties of chlorido{hydridotris[3-,5-dimethylpyrazol-1-yl-κN3]borato}(3-,5-dimethylpyrazol-1-yl-κN)copper(II), C20H30BClCuN8
  44. The crystal structure of 4-((2-hydroxynaphthalen-1-yl)(pyrrolidin-1-yl)methyl)benzonitrile, C22H20N2O
  45. Crystal structure of 4-ethyl-3-phenylisoquinolin-1(2H)-one, C17H15NO
  46. Crystal structure of (tricyclohexylphosphane-κP)-[(Z)-N-(3-fluorophenyl)-O-methylthiocarbamato-k1S]gold(I), C26H40AuFNOPS
  47. Crystal structure of (3S,8R,10R,12R,14R)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl) hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate, C32H54O4
  48. The crystal structure of 2-[(S)-1-(naphthalen-1-yl)ethyl]-2,3,7,7a- tetrahydro-3a,6-epoxyisoindol-1(6H)-one, C19H20NO2
  49. Crystal structure of {hydridotris[3-(t-butyl)-5-isopropylpyrazol-1-yl-κN3]borato}thallium(I), C30H52BN6Tl
  50. Synthesis and crystal structure of 1-octyl-3-phenylquinoxalin-2(1H)-one, C22H26N2O
  51. The crystal structure of 2,6-difluorophenol, C6H4F2O
  52. 4-(9H-Fluoren-9-yl)-4-methylmorpholin-4-ium bromide, C18H20BrNO
  53. The crystal structure of 2,4-dimethylimidazole monohydrate, C5H10N2O
  54. The crystal structure of 1,2-dimethylimidazole, C5H8N2
  55. The crystal structure of 3-ammonio-4-aminobenzoate, C7H8N2O2 – a second polymorph
  56. The crystal structure of 4-hydroxy-2,5-bis(1-methyl-1H-imidazol-3-ium-2-ylthio)-3,6-dioxocyclohexa-1,4-dienolate chloride monohydrate, C14H15N4O5S2Cl
  57. The crystal structure of butyrylferrocene, C14H16FeO
  58. The crystal structure of bi-1,1′-cyclopentane-1,1′-diol, C10H18O2
  59. The crystal structure of 2-iso-propylimidazole, C6H10N2
  60. The crystal structure of aqua-tris (1,3-diphenylpropane-1,3-dionato-κ2O,O′)-lanthanum(III), C45H35LaO7
  61. Crystal structure of (3E,5E)-3,5-bis-4-methoxy-3-(trifluoromethyl)benzylidene)-1-methylpiperidin-4-one, C24H21F6NO3
  62. The crystal structure of 3,5-dichloro-6-diazo-2,4-dinitrocyclohexa-2,4-dien-1-one, C6Cl2N4O5
  63. Crystal structure of carbonyl(2-methylquinolin-8-olato-κ2N,O)(triphenylarsine-κAs)rhodium(I), C29H23AsNO2Rh
  64. Crystal structure of (1aS,1a1S,2S)-4a-butoxy-1a,1a1,2,4a,5,6-hexahydro-1H-cyclobuta[de]naphthalen-2-yl-4-nitrobenzoate, C22H25NO5
  65. Crystal structure of carbonyl(2-oxopyridin-1(2H)-olato-k2O,O′)(triphenylarsine-κAs)rhodium(I), C24H19AsNO3Rh
  66. Crystal structure of catena-poly[triqua-bis(μ2-4-carboxy-2-(1H-tetrazol-1-yl)-1H-imidazole-5-carboxylato-k3N,O:O′)barium(II)] tetrahydrate, C14H14BaN12O15
  67. Crystal structure of (E)-3′,6′-bis(ethylamino)-2-((quinoxalin-2-ylmethylene)amino)spiro[isoindoline-1,9′-xanthen]-3-one, C35H32N6O2
  68. Crystal structure of diaqua-bis(μ2-5-chloro-salicylato-κ3O,O′:O′)-bis(5-chloro-salicylato-κ2O,O′)-bis(1,10-phenanthroline-κ2N,N′) dilead(II) – water (1/2), C52H36C14N4O14Pb2·2(H2O)
  69. Crystal structure of (E)-2-(4-ethoxycarbonyl-3,5-dimethyl-2-(pyrrole-2-ylmethyleneamino)-3′,6′-dihydroxylspiro[isoindoline-1,9′-xanthen]-3-one-methanol (1/1), C31H29N3O7
  70. The crystal structure of 5H-dibenzo[b,e]azepine-6,11-dione, C14H9NO2
  71. Crystal structure of (E)-2-(4-fluoro-2-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
  72. The crystal structure of N-(2-methoxy-4,5-bis[phenylselanyl]phenyl)picolinamide, C25H20N2O2Se2
  73. The crystal structure of (E)-2-(5-bromo-2-hydroxybenzylidene)-N-phenylhydrazine-1- carboxamide monohydrate, C14H14BrN3O3
  74. Crystal structure of fac-tricarbonyl-(nitrato-k1O)-bis(pyridine-κN)-rhenium, C13H10O6N3Re
  75. Crystal structure of (E)-2-(((1H-pyrrol-2-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one — methanol (1/2), C27H25N3O6
  76. The crystal structure of 4-amino-N′-(4-aminobenzoyl)benzohydrazide monohydrate, C14H16N4O3
  77. Crystal structure of bis(amino(carbamothioylamino)methaniminium) 5-hydroxyisophthalate monohydrate, C12H20N8O6S2
  78. The crystal structure of 2-(chloromethyl)pyridine, C6H6ClN
  79. The crystal structure of 1-bromo-4-iodo-benzene, C6H4BrI
  80. The crystal structure of 2,6-dimethyl-4-nitro-phenol, C8H9NO3
  81. The crystal structure of 3-chloropropionic acid, C3H5ClO2
  82. The crystal structure of 2-(2-methoxyphenyl)acetic acid, C9H10O3
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2020-0469/html
Scroll to top button